Condition (MeSH)
Cytomegalovirus Retinitis
ClinicalTrials.gov lists 64 trials for Cytomegalovirus Retinitis or a narrower condition beneath it. National Institute of Allergy and Infectious Diseases (NIAID) has the most among industry and government lead sponsors, with 21.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
64 of the 64 trials are tagged with Cytomegalovirus Retinitis itself; the rest are tagged with a narrower condition beneath it.
When did Cytomegalovirus Retinitis trials start? (12)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 2
- Phase 2/3
- Phase 3
- Phase 4
- Observational
Top of scale: 3
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 1 |
| 2023 | 1 |
| 2021 | 1 |
| 2011 | 1 |
| 2004 | 1 |
| 2002 | 1 |
| 1998 | 1 |
| 1997 | 3 |
| 1995 | 2 |
| 1994 | 1 |
Showing 10 of 12 earlier years.
No forecast is made for this condition: it averages 0.4 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: none of the 64 trials evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Cytomegalovirus Retinitis trials in? (7)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 9 |
| Phase 2 | 11 |
| Phase 2/3 | 2 |
| Phase 3 | 9 |
| Phase 4 | 3 |
| Not applicable | 23 |
| Observational | 7 |
How many Cytomegalovirus Retinitis trials are recruiting? (4)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Recruiting | 2 |
| Completed | 57 |
| Withdrawn | 2 |
| Unknown status | 3 |
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Cytomegalovirus Retinitis trials? (9)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| National Institute of Allergy and Infectious Diseases (NIAID) | 21 |
| Hoffmann-La Roche | 9 |
| Astra USA | 4 |
| Ionis Pharmaceuticals, Inc. | 4 |
| Gilead Sciences | 3 |
Showing 5 of 9 sponsors.
Which drugs are being tested for Cytomegalovirus Retinitis? (8)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| Ganciclovir | 28 |
| Foscarnet | 13 |
| Cidofovir | 9 |
| Probenecid | 5 |
| Sevirumab | 4 |
Showing 5 of 8 drugs.
Interventions as named in the registry (7)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| Valganciclovir | 3 |
| Sagramostim | 2 |
| Acyclovir 5% | 1 |
| LB-DTK-CMV | 1 |
| Low-dose Aldesleukin (Proleukin®) | 1 |
Showing 5 of 7 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Cytomegalovirus Retinitis trials report? (4)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Opportunistic Infection | 133 | 1 |
| Neutropenia | 124 | 1 |
| Thrombocytopenia | 37 | 1 |
| Proteinuria 2+ | 24 | 1 |
Which publications cover Cytomegalovirus Retinitis? (93)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Viral-specific T cells for Cytomegalovirus retinitis following hematopoietic stem cell transplantation: A success story. | Pediatric blood & cancer | 2023 | Yes |
| A Simplified CMV-specific T Cell Transfer Targeting Drug-resistant CMV Retinitis. | Ocular immunology and inflammation | 2022 | Yes |
| Classification Criteria for Cytomegalovirus Retinitis. | American journal of ophthalmology | 2021 | Yes |
| Ocular Outcomes after Treatment of Cytomegalovirus Retinitis Using Adoptive Immunotherapy with Cytomegalovirus-Specific Cytotoxic T Lymphocytes. | Ophthalmology. Retina | 2021 | Yes |
| Incidence, risk factors, and outcomes of cytomegalovirus retinitis after haploidentical hematopoietic stem cell transplantation. | Bone marrow transplantation | 2020 | Yes |
Showing 5 of 93 publications.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: prevalence, rare-disease identity, and sub-conditions in mesh.